AstraZeneca to strengthen presence in California with new South San Francisco location

Move will create scientific site for more than 350 local employees 

AstraZeneca, together with its global biologics research and development arm MedImmune, today revealed plans to bring together five of its Bay Area sites into one location in South San Francisco. The new site will be located in the Cove at Oyster Point with cutting-edge lab space and offices. More than 350 employees in existing AstraZeneca, Acerta Pharma, MedImmune, and Pearl R&D facilities will move to the new location beginning in Q4 2017. 

The move demonstrates AstraZeneca’s continued commitment and investment in a strong and visible presence in California, and the new location will serve as a valuable source of talent and partnership opportunities, as well as provide convenient access to strategic suppliers. Additionally, it will serve to strengthen the company’s presence in the Bay Area biopharma landscape, which remains a leading global bioscience cluster. The company also anticipates some cost benefits associated with the move, such as better space utilization, improved energy efficiency, and other operating benefits.

Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “Our new South San Francisco location—where biotech and Silicon Valley intersect—brings all of our California employees to one site and provides opportunities to access exciting science both inside and outside our walls. We are proud to create an open, welcoming, and vibrant center that will inspire our teams and partners to continue to push the boundaries of scientific innovation.”

The Cove will offer modern, energizing, and collaborative facilities that AstraZeneca and its subsidiaries are known for providing to employees. In addition to housing best-in-science laboratory technology, the campus provides access to a host of shared amenities and conveniences including Caltrain, BART, ferry transportation, fitness and recreation, restaurants, and shopping. 

Dr. Bahija Jallal, Executive Vice President at MedImmune, said: “MedImmune has long been committed to our employees and the vibrant scientific community in California. Our new facility will bring our teams together under one roof and strengthen our focus on combining the expertise across our business to develop new ways to treat patients in areas such an oncology, respiratory and cardiovascular and metabolic disease.”

ZS Pharma, a San-Francisco based company who joined the AstraZeneca group in December 2015, is currently not included in the planned move and will revisit the decision in 2017.  

Acerta Pharma, a biotech focused on developing innovative therapies for blood cancers, is a company in which AstraZeneca has a majority equity investment, and Pearl Therapeutics is a wholly owned subsidiary of AstraZeneca following its acquisition in 2013.  

NOTES TO EDITORS

About MedImmune
MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across Respiratory & Autoimmunity, Cardiovascular & Metabolic Diseases, Oncology, and Infection and Vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centres, with additional sites in Cambridge, UK and Mountain View, CA. For more information, please visit www.medimmune.com.

About AstraZeneca and Acerta Pharma
AstraZeneca acquired a majority stake interest in Acerta Pharma and its core asset, acalabrutinib in February 2016.  Acerta Pharma serves as AstraZeneca’s hematology Center of Excellence and the Acerta employees provide substantial and valuable expertise in blood cancers.  

About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas – Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca-us.com    

CONTACTS

Media Inquiries

Michele Meixell                        +1 302 885 2677

Tracy Rossin                           +1 301 219 9630